|
Thalassaemia, Cancer and other Diseases related to Metal and Free Radical Imbalance and Toxicity |
|
|
Pre- and post- conference tours are available, which can be booked directly with the official travel agent of the conference as described in the sub-section Travel in the 16th ICOC website (www.icoc-isocam.org),
Wednesday 25th October - Pre-conference Tours
Thursday 26th October - Pre-conference Tours
Venue: Miramare Beach Hotel, Limassol, Cyprus.
Fiday 27th October
15.00-18.00 h Registration:
18.00 h Opening
Welcome Addresses by Local and International Organisations
18.30 h Kontoghiorghes GJ: Recent advances in science. Applications of chelation in science and medicine.
18.50 h Marx JJM: Recent advances in medicine. From the iron age to new genes and new diseases
19.10 h Kolnagou A: Welcome to Cyprus
19.30 h Welcome Reception
Miramare Beach Hotel: Drinks and Snacs
Saturday 28th October
Session 1:
9.00- 10.30 h
Keynote Lectures on Iron Metabolism and Toxixity
Chair: Marx JJM and Richardson DR
Ponka P: Recent Advances in Physiology and Pathophysiology of Iron Metabolism
Pantopoulos K: Iron regulatory proteins: role in health and disease
Afanasiev I B: The role and control of free radicals in medicine
Weinberg ED: Iron out-of-balance: a risk factor for acute and chronic disease
Round Table Discussion
10.30- 10.50 h Tea Break /Poster Viewing
Session 2:
10.50- 12.40 h
Clinical Studies: Effective Chelation Therapy using Deferiprone (L1) / Deferoxamine Combination in Thalassaemia patients
Chair: Aessopos A and Aydinok Y
Tondury P et al: Over 17 years of experience with deferiprone in Switzerland
Manz C et al: A randomized controlled trial comparing the combination therapy of deferiprone (L1) and desferrioxamine (DFO) versus L1 or DFO monotherapy in patients with thalassemia major
Tsironi M et al: Effects of combined chelation therapy on serum ferritin levels and T2* values
Yazman D et al: Comparison of the efficacy of combined chelation of deferiprone and deferoxamine with other treatments on myocardial iron load in thalassaemia patients
Kolnagou A et al: Normalisation of serum ferritin, cardiac and liver iron in thalassaemia patients using the ICOC chelation protocol of deferiprone (L1) / deferoxamine combination
Round Table Discussion
12.40- 14.00 h Lunch Break
Session 3:
14.00- 15.30 h
Pathological Aspects of Cardiotoxicity and other forms of Iron Overload Toxicity. Cardioprotection by Deferiprone (L1)
Chair: Wood JC and Pharmaki K
Kyriacou K et al: Loss of myofibers and disruption of myocytes is the potential mechanism of iron overload toxicity in cardiomyopathy in iron loaded thalassaemia patients. Histopathological and electron microscopy findings.
Aydinok Y et al: Randomised controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy to assess NTBI and total iron excretion in patients with thalassaemia major
Spino M et al: Exploring the mechanisms underlying the cardioprotective effects of deferiprone
Peng C T: The cardiac function improvement of thalassemia patients in using deferiprone (L1)
Round Table Discussion
15.30-15.50 h Tea Break/Poster Viewing
Session 4:
15. 50 - 17.20 h
Comparative Studies of Iron Overload Toxicity in Various Organs and Different Categories of Iron Loaded patients. The Effects of Chelation Therapy.
Chair: Peng CT and Kolnagou A
Wood J C et al: Renal iron deposition occurs in chronically transfused sickle cell disease but not thalassemia major
Ramazzotti A et al: Myocardial iron overload and myocardial fibrosis in thalassemia intermedia versus thalassemia major patients: a comparative multicenter study
Farmaki K et al: Improvement of glucose metabolism in patients with thalassaemia major who undergo combined chelation therapy with deferoxamine and deferiprone
Vini D et al: Fertility in thalassaemia female patients: is there something new?
Round Table Discussion
17.30-19.00 h
OPEN SESSION
Patients meet the doctors: Questions and Answers session between an expert panel of doctors and patients / parents.
Expert Panel:
(Aessopos A, Aydinok Y, Farmaki K, Kolnagou A, Maggio A, Marx JJM, Peng CT, Tondury P, Wood JC)
20.00 h
Gala Dinner: Miramare Beach Hotel
Sunday 29 October
Session 5:
9.00-10.30 h
Cardiomyopathy. Diagnostic Criteria and Chelation Therapy in Thalassaemia and Other iron Loaded Diseases
Chair: Tondury P and Lu C
Aessopos A et al: Congestive heart failure and treatment in thalassemia major. Update on the effect of chelation therapy
Wood JS et al: Iron cardiomyopathy in a patient with sickle cell anemia.
Ramazzotti A et al: ECG changes in thalassemia patients: correlations with myocardial iron overload and myocardial fibrosis
Tsironi M et al: Predictive ECHO- DOPPLER indices of left ventricular impairment in £]-thalassemic patients with ten years follow up
Round Table Discussion
10.30- 10.50 h Tea Break /Poster Viewing
Session 6:
10.50- 12.00 h
The Role of MRI T2 and T2* in Iron Overload Diagnosis and the progress of Chelation Therapy
Chair: Gotsis ED and Wood JC
Wood JC: The use of MRI for assessing iron overload and the progress of iron chelation therapy.
Gotsis ED: The uses and differences of MRI T2 and T2* in the determination of iron overload in iron loaded thalassaemia patients.
Kolnagou A et al: Maintenance of normal serum ferritin, cardiac and liver iron levels in a thalassaemia patient using deferiprone (L1) monotherapy for five years. A case report.
Round Table Discussion
Session 7:
12.00-13.00 h
Emergency Medicine and Experimental Chelators for Minimising Actinide Toxicity
Chair: Kruszewski M and Pantopoulos K
Fukuda S et al: Chelating agents for clinical application in the treatment of uranium and plutonium poisoning in radiation emergency medicine
Jin Y: DTPA administration protocol for radiological emergency medicine in nuclear fuel reprocessing plant
Fukuda S et al: Effects of CBMIDA administered orally and intraperitoneally on the removal of depleted uranium in rats
Round Table Discussion
13. 00- 14.30 h Lunch Break
14.30 Excursion to Curium and Paphos. Dinner in Paphos.
Monday 30th October
Session 8:
9.00- 10.30 h
The Role of Iron Chelating Drugs in Cancer Prevention and Treatment
Chair: Ponka P and Weinberg ED
Richardson D R et al: Recent advances in the development of cancer therapeutics in relation to iron metabolism
Kyriacou K et al: Genetic epidemiology of breast cancer; results of a population based study in Cyprus
Simunek T et al: Assessment of pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as cardioprotectants in anthracycline-induced cardiomyopathy.
Kontoghiorghes et al: New approach in the design and anticancer targeting activity of experimental and clinically used iron chelating drugs
Round Table Discusssion
10.30- 10.50 h Tea Break / Poster Viewing
Session 9:
10.50- 12.40 h
Iron Metabolism, Chelators and Antioxidants in Skin Pathology and Ageing
Chair : Wilson M T and Afanasiev IB
Korkina L: Iron in the skin physiology and pathology
De Luca C et al: Antioxidant/chelator-based individual treatments as a tool for the prevention and treatment of the aged skin
Cesario A et al: Nitrosylation of human glutathione transferase p1-1 with dinitrosyl diglutathionyl iron complex in vitro and in vivo.
Pourzand C et al: Caged-iron chelators as powerful prodrugs to protect the
skin cells against iron-mediated lysosomal damage and necrotic cell death.
Lebedev AV et al: Iron chelators and free radical scavengers among naturally occurring hydroxylated 1,4-naphthoquinones
Round Table Discusssion
12.40 - 14.00 h Lunch Break
Session 10:
14.00- 15.50 h
Metabolic Aspects of Nitric Oxide, Free Radicals and Iron in Health and Disease
Chair: Korkina L and De Luca C
Chaikovskayia N et al: Influence of NO-spin trap Fe-DETC on morphology of brain tissue, antioxidant activity and cerruloplasmin-transferrin system in blood serum in case of acute hypoxia-ischaemia using antioxidant mexidant and NOs-inhibitor iminobiotin.
Richardson DR et al: Nitrogen monoxide (NO)-mediated iron mobilization from cells is linked to NO-induced glutathione efflux via MRP1
Kruszewski M et al: Differential action of permeable and non-permeable iron chelators on formation of dinitrosyl iron complexes in vivo
Afanasiev IB: Nitric oxide and superoxide are mediators of chronic complications and premature aging in thalassemia and other hereditory diseases
Liu G et al: Skeletal free radicals mediated by iron: a new therapeutic target of postmenopausal osteoporosis using oral chelation
Round Table Discusssion
15.50-16.10 h Tea Break /Poster Viewing
Session 11:
16.10 -18.00 h
Advances in the Design of New Treatments in Iron Metabolic Disorders
Chair: Maggio A and Kontoghiorghes GJ
Wilson MT: Hemoglobin based blood substitutes
Weinberg ED: Development of protein iron chelators as pharmaceutical agents
Richardson DR et al: Mitochondrial-permeable iron chelators prevent cardiac hypertrophy in the mouse model of Friedreich's Ataxia
Pantopoulos K et al: Iron-dependent degradation of apo-irp1 by the ubiquitin-proteasome pathway
Marx JJM et al: Do iron chelators influence progression of atherosclerosis?
Round Table Discussion
18.00 - 18.30 h:
Chair : Fuguda S and Yazman D
Poster Discussion
20.00 h: Dinner in a Taverna. Cypriot Cuisine, Live music and Dancing
Tuesday 31st October
Session 13:
9.00- 10.30 h
Design of New Chelators for the Treatment of Iron Metabolic Disorders and Free Radical Toxicity
Chair: Richardson DR and Pantopoulos K
Santos AM: New developments in trivalent cation chelators: extrafunctionalization and ligand-combined strategies.
Wilson MT et al: Comparative study of iron chelators as reducing agents for ferryl heme: A mechanism to protect against oxidative stress without iron chelation.
Srichairatanakool S et al: Investigation of 3-hydroxypyridin-4-one conjugate as a novel oral iron chelator.
Lebedev AV et al: Free radical conversion of catecholates associated with chelation of calcium and other group ii metal cations
10.30-10.50 h Tea Break
Session 14:
10.50- 12.20 h
The Role of Copper, Zinc and Iron Chelators for Preventing Cardiomyopathy in Diabetes and
Chair: Santos AM and Weinberg ED
Lu C: Roles of zinc and copper in the diabetes and diabetic cardiomyopathy
Wenke F : Metallothionein regulation of hypoxia-inducible factor 1 in diabetic hearts
Lu C: Diabetic cardiomyopathy and metallothionein: what role of iron and copper play?
Li X et al : Cardiac protection of non-mitogenic human acidic fgf from oxidative damage in vitro and in vivo: potential application for the prevention of diabetic cardiomyopathy
Round Table Discussion
Session 15:
12.20 -13.00 h
Chair: Marx JJM
Future Aspects of Chelation Therapy in Iron Overload and Other Diseases
Maggio A et al: Lights and shadows in the chelation treatments
Kontoghiorghes GJ et al: Deferiprone (L1)-25th year anniversary. Its clinical use for the complete treatment of iron overload and possible uses in other diseases as monotherapy or in combination with deferoxamine, deferasirox , deferitrin and other drugs.
13.00- 13.10 h Announcement of the 17th ICOC and Close.
|
|
MAJOR TOPICS OF THE 16TH ICOC
- Oral iron chelators in the treatment of thalassemia and other diseases.
- Advances in the treatment of iron overload with Deferiprone (L1), Deferoxamine and their combination.
- The use of effective dose protocols in iron chelation therapy. The ICOC and other combination chelation therapy protocols.
- Cardioprotective effect of Deferiprone (L1) and other chelators. The role of MRI T2*
- Postmarketing Clinical results and Clinical trials with Exjade (Deferasirox, ICL670) in thalassaemia and other conditions.
- New iron chelators under development: Clinical trials with Deferitrin (GT-56 252), L1NAll, Deferoxamine polymers, PIH derivatives and other chelators.
- Iron chelation therapy in Sickle cell anaemia, Myelodysplasia, Haemolytic anaemia, Renal dialysis, Cancer and other diseases.
- Conditions associated with metal imbalance, transfusions and chelating drugs.
- Iron metabolism and iron containing proteins in normal and disease states.
- Future strategies and developments in iron and other metal chelation.
- Recent advances in thalassaemia and other haemoglobinopathies(all aspects). Including gene therapy, bone marrow transplantation, induction of HbF.
- Monitoring of iron chelation therapy with invasive and non-invasive methods (e.g. MRI T2 and T2*, Squid-Biosusceptometry,"Free" iron etc)
- Chemical, biochemical, pharmacological, toxicological, clinical and therapeutic aspects of iron and other metals, chelating agents, chelating drugs and chelator metal complexes
- Diagnosis and prevention of the toxicity of chelating drugs and metal imbalance
- Metal ions in health, disease, nutrition and diagnostic medicine
- Biology, pharmacology and toxicology of metals and chelators
- Free radicals in biology and medicine. The role of antioxidants. The role of chelators as antioxidants.
- Environmental metal toxicology
- Heavy metals and radioactive metals-Toxicity and metabolic aspects
- Therapeutic approaches in Actinide and Heavy metal toxicity.
- Cancer: causes, prevention, epidemiology and chemotherapy. Chelation therapy approaches in cancer. The role of free radicals and cancer. Prevention of doxorubicin toxicity by chelators. Clinical trials with Triapine and other chelating drugs in cancer.
- The use of chelating drugs in the treatment of Alzheimer's disease and Parkinson's disease. Clinical trials with the metal chelating drug Clioquinol in Alzheimer's disease patients and in other conditions.
- The effects of metals and free radicals in heart disease and atherosclerosis. The therapeutic effects of chelating drugs and antioxidants in these conditions.
- Epidemiological aspects of chelation therapy in thalassaemia and other diseases of metal imbalance and toxicity
- Psychological aspects of chelation and other drug therapy in thalassaemia and other diseases
- Ethical aspects of chelation therapy. Orphan drugs, orphan diseases and orphan patients in developing and developed countries.
SATELLITE SYMPOSIA
- Educational programme for Clinicians and Scientists.
- Recent advances sessions in Biochemical, Pharmaceutical and Medical sciences related to chelation therapy conditions. Recent advances lectures in related areas of Haematology, Nutrition, Cardiology, Atherosclerosis, Neurology, Gene therapy, Virology, Rheumatology, Autoimmune diseases, Medical diagnosis such as MRI, Environmental pollution and Drug design, development and application.
- Thalassaemia patient and parents meeting with a panel of Experts. Question-Answer and Discussion session.
- Special symposia on the profile of specific drugs or medical diagnostics organised by host companies.
METAL IMBALANCE AND TOXICITY CONDITIONS - CLINICAL USE OF CHELATORS
Iron overload
£]-Thalassaemia major
£]-Thalassaemia intermedia
HbE £]-Thalassaemia
HbS £]-Thalassaemia
Sickle cell anaemia
Myelodysplastic syndrome
Aplastic anaemia
Sideroblastic anaemia
Pyruvate-kinase deficiency
Blackfan-Diamond anaemia
Fanconis anaemia
Pernicious anaemias
Hereditary spherocytosis
Congenital dyserythropoietic anaemia
Congenital atransferrinaemia
Hereditary hypochromic anaemia
Haemolytic disease of the newborn
Idiopathic haemochromatosis
Iron overload in liver disease
Iron overload in haemodialysis
Prophyria cutanea tarda
Intramuscular iron dextran
Dietary or latrogenic iron intake
Iron poisoning
Other metal toxicity
Aluminium overload
Wilson's disease (Copper overload toxicity)
Plutonium, Uranium and other Actinide toxicity
Lead, Cadmium, Nickel, Mercury and other Heavy metal toxicity
Indium, Gallium, Gadolinium and other diagnostic metal toxicity
Neoplastic and other diseases
Neuroblastoma
Breast, Prostate and other forms of cancer
AIDS and other viral infections
Microbial infections
Malaria and other parasitic infections
Iron imbalance conditions
Iron deficiency anaemia
Anaemia of chronic disease
Friedreich's ataxia
Hallevorden-Spatz syndrome
Free radical and other toxicity
Conditions of free radical damage
Cyclooxygenase and lipoxygenase inhibitors
Drug toxicity eg cardiac damage by doxorubicin
Ischaemia reperfusion injury
Storage of organs for transplantation
Alzheimer's disease
Parkinson's disease
Multiple sclerosis
Rheumatoid arthritis
Autoimmune diseases
Other uses
Metal imbalance conditions
Radiopharmaceuticals
Diagnostic medicine
Magnetic resonance imaging